Xeris Biopharma Holdings Inc. Stock
A loss of -1.970% shows a downward development for Xeris Biopharma Holdings Inc..
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 8 € there is a hugely positive potential of 55.88% for Xeris Biopharma Holdings Inc. compared to the current price of 5.13 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -1.970% | -1.497% | 2.681% | 45.382% | -18.733% | 170.105% | 43.673% |
| Heron Therapeutics Inc. | -0.770% | 1.801% | -17.320% | -57.946% | -36.580% | -71.740% | -95.128% |
| Evolus Inc | -0.560% | 4.046% | -22.078% | -56.098% | -33.945% | -51.351% | -67.857% |
| Sangamo Therapeutics Inc. | 1.720% | -15.717% | -37.386% | -65.319% | -36.993% | -83.471% | -97.618% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat